French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum influenza vaccine, demonstrated a strong safety profile and immune response when administered alongside a conventional flu shot.
The findings, now available in the journal Vaccines, stem from a 180-person study evaluating the co-administration of OVX836 with GSK’s (LSE: GSK) Fluarix Tetra (influenza virus haemagglutinin).
According to Osivax, the trial showed no serious or unsolicited side effects. Local and systemic reactions were consistent across all groups, regardless of treatment. In addition, the standard immune response to Fluarix Tetra remained intact when given with OVX836, and a separate, strong immune reaction to OVX836 itself was observed in relevant groups.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your account
Try before you buy
Free
7 day trial access
Take a Free Trial
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
Subscribe Now
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK